• 1.

    Barylski M, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72:3544.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Haas ME, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 2016; 134:6172.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Farnier M, et al. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY phase 3 clinical program trials. Int J Cardiol 2016; 223:750757.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:17131722.

  • 5.

    Toth PP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 2018; 93:13971408.

EMERGING THERAPIES FOR CARDIOVASCULAR DISEASE: PCSK9 Inhibitors and Their Potential Role in Patients with CKD

  • 1 Sonali Gupta, MD, is associated with the University of Rochester, Rochester, New York. Yifeng Yang, MD, Mohammed Elsadany, MD, and Joseph Mattana, MD, are associated with St. Vincent’s Medical Center, Bridgeport, Connecticut, and the Quinnipiac University Frank H. Netter MD School of Medicine, North Haven, Connecticut.
Restricted access
Save